Lecrubier Y, Bakker A, Dunbar G, Judge R
INSERM, Hopital La Salpetriere, Paris, France.
Acta Psychiatr Scand. 1997 Feb;95(2):145-52. doi: 10.1111/j.1600-0447.1997.tb00388.x.
The aim of this 12-week, double-blind, parallel group, placebo-controlled study was to compare paroxetine with clomipramine in 367 patients with DSM-III-R defined panic disorder. Efficacy assessments included the daily panic attack diary, the Clinical Global Impression Scale, the Hamilton Anxiety Rating Scale, the Marks Sheehan Phobia Scale and the Sheehan Disability Scale. Paroxetine produced significant improvements compared with placebo in various measurements of panic attack frequency, and was as effective as clomipramine. However, paroxetine appeared to have a more rapid onset of action than clomipramine in reducing the number of panic attacks to zero. There was an equivalent improvement with both paroxetine and clomipramine in the supportive efficacy variables which assessed associated aspects of therapeutic improvement. Significantly more adverse effects were reported in the clomipramine group compared with the paroxetine group, while there was no difference between the paroxetine and placebo groups.
这项为期12周的双盲、平行组、安慰剂对照研究旨在比较帕罗西汀与氯米帕明对367例符合DSM-III-R标准的惊恐障碍患者的疗效。疗效评估包括每日惊恐发作日记、临床总体印象量表、汉密尔顿焦虑量表、马克斯-希恩恐惧症量表和希恩功能障碍量表。与安慰剂相比，帕罗西汀在惊恐发作频率的各项测量指标上均有显著改善，且与氯米帕明疗效相当。然而，在将惊恐发作次数降至零方面，帕罗西汀的起效似乎比氯米帕明更快。在评估治疗改善相关方面的支持性疗效变量上，帕罗西汀和氯米帕明的改善程度相当。与帕罗西汀组相比，氯米帕明组报告的不良反应明显更多，而帕罗西汀组与安慰剂组之间则无差异。
